Advisory Services Network’s CytomX Therapeutics CTMX Stock Holding History

Advisory Services Network’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-274	Closed	-$1.29K	–	2694
2026 Q1	$1.29K	Buy	+274	New	+$1.39K	﹤0.01%	4253
2025 Q4	–	Sell	-274	Closed	-$874	–	2341
2025 Q3	$874	Buy	+274	New	+$617	﹤0.01%	3958
2024 Q1	–	Sell	-274	Closed	-$425	–	1913
2023 Q4	$425	Buy	+274	New	+$360	﹤0.01%	3646
2023 Q2	–	Sell	-412	Closed	-$622	–	1915
2023 Q1	$622	Hold	412	–	–	﹤0.01%	3705
2022 Q4	$659	Buy	+412	New	+$610	﹤0.01%	3691
2021 Q3	–	Sell	-412	Closed	-$3K	–	1791
2021 Q2	$3K	Buy	+412	New	+$3.21K	﹤0.01%	3201
2021 Q1	–	Sell	-412	Closed	-$3K	–	1630
2020 Q4	$3K	Sell	412 -4	-1%	-$29	﹤0.01%	2862
2020 Q3	$3K	Buy	+416	New	+$3.08K	﹤0.01%	2930
2020 Q2	–	Sell	-412	Closed	-$3K	–	1368
2020 Q1	$3K	Buy	412 +274	+199%	+$1.91K	﹤0.01%	2628
2019 Q4	$1K	Buy	+138	New	+$931	﹤0.01%	2929

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Advisory Services Network's CTMX Position: Q2 2026 in Review

Advisory Services Network sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 274 shares — an estimated $1.29K sold.

Advisory Services Network first reported a position in CTMX in Q4 2019 and held it in 10 quarters. The position peaked at $3K in Q2 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Advisory Services Network reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 274 CytomX Therapeutics shares in Q2 2026, an estimated $1.29K.
Advisory Services Network first reported a position in CytomX Therapeutics in Q4 2019 and held it in 10 quarters.
Advisory Services Network's CytomX Therapeutics position peaked at $3K in Q2 2021.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.